Cell culture studies on the mechanism of action of chemical carcinogens and tumor promoters.
The evolution of a fully malignant tumor is a multistep process resulting from the action of multiple factors, both environmental and endogenous, and involves alterations in the function of multiple cellular genes. Chemical carcinogens that initiate this process appear to do so by damaging cellular DNA. In addition to producing simple point mutations, this damage appears to induce the synthesis of a trans acting factor that can induce asynchronous DNA replication. This response may result in gene amplification and/or gene rearrangement. This phenomenon may also play a role in synergistic interactions between chemicals and viruses in the causation of certain cancers. The primary target of the tumor promoters TPA, teleocidin, and aplysiatoxin appears to be the cell membrane. All three of these agents act, at least in part, by enhancing the activity of the phospholipid-dependent enzyme protein kinase C. We have proposed a stereochemical model to explain the interaction of these amphiphilic compounds with the PKC system. We have found that TPA and teleocidin markedly enhance the transformation of C3H 10T1/2 mouse fibroblasts when these cells are transfected with the cloned H-ras human bladder cancer oncogene. Thus, tumor promoters can act synergistically with an activated oncogene to enhance cell transformation. Furthermore, carcinogen-transformed rodent cells display aberrations in the expression of various endogenous retrovirus-related sequences. Activation of some of these sequences may lead to insertion mutations and further aberrations in gene expression. Thus, multistage carcinogenesis may involve both changes in cellular oncogenes and aberrations in the function of DNA sequences that control gene transcription.
D000818:Animals; D002273:Carcinogens / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology; D004273:DNA, Neoplasm / Q000235:genetics; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D005784:Gene Amplification / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D008235:Lyngbya Toxins; D009153:Mutagens; D009857:Oncogenes; D011493:Protein Kinase C / Q000378:metabolism; D013329:Structure-Activity Relationship; D013755:Tetradecanoylphorbol Acetate; D014158:Transcription, Genetic / Q000187:drug effects
D002273:Carcinogens; D004273:DNA, Neoplasm; D008235:Lyngbya Toxins; D009153:Mutagens; C006610:aplysiatoxin; C022229:dihydroteleocidin B; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate